MK-677 (ibutamoren) reliably increases appetite in most people who take it. In a year-long placebo-controlled trial of healthy older adults, about two-thirds of those given MK-677 reported a noticeable rise in hunger, compared to roughly a third on placebo. The hunger tends to be strongest in the first weeks and fades over time for many users, but the experience varies and understanding why it happens reveals a lot about what MK-677 actually does inside the body.
Why MK-677 Makes You Hungry
MK-677 was designed to mimic ghrelin, the hormone your stomach releases when it’s empty. Ghrelin is sometimes called the “hunger hormone” because its primary job is to tell your brain it’s time to eat. MK-677 binds to the same receptor that ghrelin uses, called the growth hormone secretagogue receptor, and trips many of the same downstream signals. One of those signals is the activation of appetite-stimulating neurons in a part of the brain called the arcuate nucleus of the hypothalamus. Research in mice has confirmed that MK-677 and related compounds activate these neurons, which produce neuropeptide Y and agouti-related peptide, two of the brain’s most potent appetite-driving chemicals.1Endocrinology. Intranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice
This is not an accidental side effect. Ghrelin mimicry is the core mechanism of MK-677, and appetite stimulation is a direct, pharmacological consequence of flipping that switch. If you take a compound that acts like the hunger hormone, you should expect to feel hungrier. The question people usually want answered is how much hungrier and for how long.
How Strong Is the Hunger and How Long Does It Last?
The best data comes from a randomized, placebo-controlled trial that followed healthy adults aged 60 to 81 for a full year. In that study, 67% of participants taking MK-677 at 25 mg per day reported increased appetite, compared to 36% on placebo. That gap is statistically significant and clinically meaningful: you’re roughly twice as likely to notice a real appetite boost on MK-677 as you are to experience a placebo-related perception of hunger.2PubMed Central. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial – Section: Results
The encouraging part for people worried about uncontrollable cravings is that the hunger does fade. Among MK-677 users who reported increased appetite, half said it returned to normal within three months. The other half saw it taper more gradually.2PubMed Central. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial – Section: Results This pattern of initial spike followed by adaptation is consistent with how the body typically responds to sustained receptor stimulation: the signaling pathway gradually dials itself down when the stimulus stays constant. The first few weeks are usually the peak of it.
That said, the trial studied older adults, and younger users in the fitness community sometimes report hunger that is intense enough to interfere with calorie-controlled diets in the early weeks. Individual responses vary, and there’s no published dose-finding study specifically designed to quantify appetite changes at different dosages in younger populations. The 25 mg daily dose used in most clinical trials is also the dose most commonly discussed in self-experimentation communities, so the hunger data at least roughly maps to real-world use.
Practical Strategies People Use to Manage the Hunger
Because the appetite spike is front-loaded, many users experiment with timing and dosing to blunt its impact. Taking MK-677 right before bed is one of the most common approaches. The logic is straightforward: if you’re asleep during the window when the ghrelin-mimicking effect is strongest, you’re less likely to act on the hunger signal. Some users also start at lower doses and gradually work up to give their body time to adjust, though there is no clinical trial data comparing appetite outcomes across different titration schedules.
For people using MK-677 specifically to gain weight, whether for bodybuilding, recovery from illness, or age-related muscle loss, the appetite increase is actually the point. One of the compound’s original research motivations was addressing the physiological loss of appetite that contributes to wasting in elderly and frail populations. The researchers in the year-long trial explicitly noted that the transient appetite increase “might counteract physiological anorexia, which is one cause of weight loss in the elderly.”2PubMed Central. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial – Section: Results So whether the hunger is a problem or a benefit depends entirely on what you’re trying to accomplish.
What MK-677 Does Beyond Appetite
The hunger gets the most attention because it’s the first thing users notice, but ghrelin receptor activation sets off a broader hormonal cascade. The primary reason MK-677 was developed was to stimulate growth hormone (GH) release from the pituitary gland, and it does this effectively. A two-month trial in obese subjects found that MK-677 significantly increased GH secretion and raised IGF-1 levels, while also increasing fat-free mass and energy expenditure.3The Journal of Clinical Endocrinology & Metabolism. Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure It also briefly raised prolactin levels, though these effects were strongest after the initial dose and diminished with continued use.
A concern people often raise is whether MK-677 disrupts cortisol, the body’s main stress hormone. The evidence here is reassuring. A week-long trial in healthy young men found that MK-677 did not meaningfully change 24-hour cortisol levels. While there was a slight shift in the timing of cortisol’s natural daily rhythm, the total amount of cortisol produced over the day, whether measured in blood or urine, stayed the same as placebo.4PubMed. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men The two-month obesity trial confirmed this over a longer period: cortisol levels at both two and eight weeks were no different from placebo.3The Journal of Clinical Endocrinology & Metabolism. Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure Any cortisol effects seem to be brief and clinically insignificant.
MK-677 and Sleep
One of the less discussed but more interesting effects of MK-677 is what it does to sleep architecture. A placebo-controlled study found that in young adults, high-dose MK-677 increased the duration of deep sleep (stage IV) by roughly 50% and boosted REM sleep by more than 20%. The proportion of abnormal sleep patterns dropped from 42% on placebo to just 8% on MK-677. In older adults, the compound produced a similar boost in REM sleep of nearly 50% and shortened the time it took to enter REM.5PubMed. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man
These findings matter in a practical sense for two reasons. First, deep sleep is when the body does most of its tissue repair and when GH secretion naturally peaks. A compound that both raises GH and deepens sleep could theoretically amplify recovery in ways that go beyond simple hormone levels. Second, the sleep benefit may be part of why taking MK-677 before bed has become the most popular dosing strategy in user communities: you potentially manage the appetite spike by sleeping through it while also maximizing the sleep-quality payoff.
Effects on Bone Turnover
Because MK-677 raises IGF-1 levels, researchers have also explored its effects on bone. Across three placebo-controlled studies involving 187 elderly adults, MK-677 treatment for nine weeks increased serum osteocalcin, a marker of bone formation, by about 29%. A second bone formation marker rose by about 10%, and a marker of bone resorption increased by roughly 23%.6Journal of Bone and Mineral Research. Oral Administration of the Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults Elevated turnover means both building and breaking down are happening faster, which is what you’d expect when GH and IGF-1 levels rise. Whether this translates into stronger bones over time or just faster cycling depends on factors like duration of treatment and the balance between formation and resorption, and no long-term fracture-outcome data from MK-677 trials has settled that question.
For the average person interested in MK-677, the bone data matters mainly as context. It confirms that the compound has real systemic effects beyond appetite and growth hormone, which is worth knowing if you’re evaluating the overall risk-benefit profile of something you’re putting in your body daily.
Common Misconceptions About MK-677 and Hunger
One persistent idea in online communities is that MK-677’s appetite effect is dose-dependent in a simple linear way, meaning if you halve the dose you halve the hunger. The clinical data doesn’t directly test this at multiple dose levels for appetite specifically, so the assumption is largely anecdotal. What is known is that the ghrelin receptor system doesn’t always respond to agonists in a clean dose-response curve, and some users report that even modest doses trigger significant hunger while others tolerate full doses without much change. Individual sensitivity to ghrelin-pathway activation likely plays a larger role than dose alone.
Another misconception is that the hunger MK-677 causes is qualitatively different from normal hunger, described in forums as a “ravenous,” “insatiable” feeling unlike anything experienced naturally. While MK-677 does activate the same neurological pathway as ghrelin, it does so with a longer duration of action since it has a half-life of several hours compared to ghrelin’s roughly half-hour lifespan in circulation. The result can feel like a sustained, deep hunger rather than the wave-like appetite fluctuations you experience normally. But it’s the same hunger signaling system, not a different kind of hunger. The intensity fades as the body adapts, as the trial data on three-month normalization demonstrates.
A third misunderstanding is that MK-677 makes you gain fat directly. MK-677 doesn’t have inherent fat-storing properties. What it does is make you want to eat more. If you eat more calories than you burn, you gain fat, whether or not MK-677 is involved. The compound itself actually increased fat-free mass and energy expenditure in the obesity trial, meaning the direct metabolic effects lean slightly toward favorable body composition. The fat gain that some users report is almost certainly a consequence of responding to the increased appetite with a caloric surplus, not a pharmacological effect of the compound on fat tissue.
Regulatory Status and What That Means for Users
MK-677 is not approved by the FDA for any medical use. It was developed by Merck and went through several clinical trials in the late 1990s and 2000s, but it never completed the full approval pathway. It is currently sold as a “research chemical” by various online suppliers, which places it in a legal gray area in many countries. In the United States, the FDA has issued warnings about products marketed as dietary supplements that contain substances like MK-677, classifying them as unapproved drugs.
The practical consequence of this regulatory limbo is quality control. Pharmaceutical-grade MK-677 used in the clinical trials discussed above was manufactured under strict conditions. The MK-677 available from online vendors has no such guarantee. Independent testing by third-party labs has occasionally found products labeled as MK-677 that were underdosed, overdosed, or contaminated with other substances. If you’re using MK-677 and experiencing appetite changes that seem extreme compared to what the clinical literature describes, product quality is a variable worth considering.
The clinical trials also studied MK-677 in populations with specific characteristics: older adults, obese individuals, healthy young men. No large trial has studied the compound in the population that most commonly uses it today, which is young to middle-aged men interested in physique or performance enhancement. The hunger data, the GH data, and the sleep data all come from populations that may not perfectly match the typical user. The direction of the effects is likely similar, but the magnitude could differ in ways that haven’t been measured.
MK-677 Compared to Exogenous Growth Hormone
People often consider MK-677 as a cheaper, oral alternative to injectable growth hormone. On the appetite front, the two diverge significantly. Exogenous GH does not activate the ghrelin receptor and does not typically cause increased hunger. MK-677, because it works upstream by mimicking ghrelin to trigger the body’s own GH release, inherently engages the appetite system as a side effect. You can’t separate the hunger from the GH-boosting mechanism because they flow from the same receptor activation.
The GH increase from MK-677 is also more modest and more physiological in pattern than what you get from injecting synthetic growth hormone. In the seven-day trial of young men, MK-677 raised IGF-1 levels and amplified the pulsatile pattern of GH release, particularly during sleep, but it didn’t produce the supraphysiological spikes that come with injection.4PubMed. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men For some users this is a selling point: you get a gentler, sustained elevation rather than a pharmacological hammer. For others, the lower peak GH levels make MK-677 less appealing for aggressive performance goals. Either way, the appetite trade-off is unique to MK-677 and does not come with injectable GH, which is information that matters if hunger management is a priority in your decision-making.
Blood Sugar and Insulin Sensitivity
One area where MK-677’s effects deserve caution is glucose metabolism. Growth hormone in general tends to reduce insulin sensitivity, and MK-677 is no exception. In the year-long trial of older adults, researchers observed changes in fasting glucose and insulin that are consistent with mildly impaired insulin sensitivity. For most healthy individuals, this effect is manageable and reversible after stopping the compound. But for anyone with prediabetes, type 2 diabetes, or significant insulin resistance, MK-677 could meaningfully worsen blood sugar control.
This is relevant to the appetite question because insulin resistance itself can alter hunger signaling. When insulin isn’t working efficiently, cells don’t get the “fed” signal as clearly, which can perpetuate a feeling of hunger even after eating. In theory, MK-677’s direct ghrelin-mimicking appetite boost could compound with its insulin-sensitizing effects to create a hunger signal that feels harder to satisfy than the ghrelin pathway alone would produce. No study has isolated this interaction specifically, but users who notice that their appetite on MK-677 seems disproportionate to what the trials describe, or that it doesn’t fade on the expected timeline, may want to monitor their fasting glucose and consider whether metabolic factors are playing a role.